Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Bid focus on Zeneca

Article Abstract:

Zeneca, a UK pharmaceuticals company, has been the subject of rumors of a takeover in 1995. Four of six stockbrokers class these shares as worth holding, a fifth argues for add, and a sixth sees a likely outperformance. Lehman Brothers forecasts outperformance and sees the company's shares as predictable, with Zeneca less likely to be acquired than itself buying another company. NatWest argues for adding to holdings. Salomon Brothers is among the holders.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Zeneca: a bid too high

Article Abstract:

Zeneca has seen a rise in its share price and no broker from a sample of six rates the company's shares a sell. There are three buyers and three holders from this sample asked about Zeneca shares. BZW and Merrill Lynch are among the buyers and have hopes for Zeneca's agrochemicals. Lehman Brothers is also a buyer, while Morgan Stanley rates Zeneca shares a hold due to weaknesses for some drugs. NatWest also rates the shares a hold, as does Hoare Govett.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
Pesticide and Other Agricultural Chemical Manufacturing, Agricultural chemicals, not elsewhere classified, Fungicides

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Zomig lifts Zeneca

Article Abstract:

Zeneca has seen a rise in its share price in the two years to April 1997. The company has launched Zomig, a migraine treatment, and this has helped its share price rise. Four brokers from a sample of six rate the company's shares a buy, one rates them a hold, and the sixth sees the shares as overvalued. The buyers include BZW, Merrill Lynch, and Lehman Brothers. The holder is Robert Fleming, while ABN-AMRO Hoare Govett sees the shares as overvalued.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1997

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, Drugs, Securities, Zeneca Ltd.
Similar abstracts:
  • Abstracts: Solid foundations. Tell it big. Until the pips squeak
  • Abstracts: Statement for a new generation. The essence of an entity. Landfill liability: a new Public Sector Handbook section gives guidance to governments on the recognition and measurement of closure and post-closure liability of solid-waste landfill sites
  • Abstracts: Housing market: a burden on builders. Developers turn bullish. Housing: the temptation to tamper
  • Abstracts: Pension compensation fiasco. Large lets multi-tied genie loose. Putting the trust back in life
  • Abstracts: Safety-first funds lead bond Pep race. Unit trusts: disclosure rules under fire. Picking the perfect Pep
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.